Alto Neuroscience Q2 EPS $(0.60) Beats $(0.63) Estimate
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience (NYSE:ANRO) reported a Q2 EPS of $(0.60), beating the analyst estimate of $(0.63) by 4.76%. This represents a significant improvement from the $(2.33) per share loss in the same period last year.
August 13, 2024 | 8:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alto Neuroscience reported a Q2 EPS of $(0.60), beating the analyst estimate of $(0.63) by 4.76%. This is a significant improvement from the $(2.33) per share loss in the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100